Glucose Teva

Glucose Teva is a pharmaceutical preparation containing glucose as the sole active ingredient. It is supplied as a sterile solution for epidural, intrabursal, and intracoronary administration. The product is manufactured for the European market and meets EU pharmaceutical standards. It provides a carbohydrate source for clinical situations that specifically require direct tissue exposure.

Glucose Teva is employed in clinical settings where a direct source of glucose is needed for local tissue metabolism or procedural support.

- Provides an immediate carbohydrate substrate during epidural procedures. - Serves as an energy source in intrabursal injections for joint interventions. - Used as a glucose infusion in intracoronary applications during cardiac catheterisation. - Supports metabolic needs of tissues exposed to ischemia in surgical contexts. - May be utilised in research protocols requiring sterile glucose solutions.

Adverse reactions to Glucose Teva are generally related to the route of administration and the sterile solution itself.

Common: - Local pain or discomfort at the injection site. - Mild erythema or bruising. - Transient headache. - Nausea or mild dizziness. - Temporary increase in blood glucose levels.

Serious: - Infection at the administration site. - Allergic or hypersensitivity reaction (rash, urticaria, anaphylaxis). - Embolism or vascular occlusion. - Severe hypotension or cardiovascular instability. - Tissue necrosis or ulceration.

When using Glucose Teva, clinicians should observe standard aseptic technique and consider patient‑specific factors to minimise risk.

- Verify sterility and integrity of the container before use. - Assess patient’s glucose tolerance and diabetic status. - Use only the intended routes (epidural, intrabursal, intracoronary); other routes are not approved. - Monitor vital signs and blood glucose during and after administration. - Avoid administration in patients with known hypersensitivity to glucose solutions. - Store according to manufacturer’s instructions to maintain solution stability.

Glucose solutions can interact with other agents administered intravenously or locally; awareness of potential interactions helps ensure safe use.

Avoid: - Co‑administration with hyperosmolar agents that may increase risk of local tissue injury. - Simultaneous injection of particulate suspensions that could precipitate emboli.

Use with caution: - Concurrent use of insulin or other glucose‑lowering medications; monitor blood glucose closely. - Combination with vasoconstrictors that may affect local circulation. - Administration alongside contrast media in coronary procedures; observe for additive osmolar load. - Use with other epidural drugs that may alter analgesic efficacy or cause additive side effects.